Chinese Japanese Germany Korea
ChemicalBook >> CAS DataBase List >>Crizotinib acetate

Crizotinib acetate

Crizotinib acetate Structure
Crizotinib acetate structure
CAS No.
877399-53-6
Chemical Name:
Crizotinib acetate
Synonyms
Crizotinib acetate
CBNumber:
CB25820320
Molecular Formula:
C23H26Cl2FN5O3
Molecular Weight:
510.39
MDL Number:
MOL File:
877399-53-6.mol
MSDS File:
SDS
Last updated:2026-07-27 17:00:41
Request For Quotation

Crizotinib acetate Chemical Properties, Uses, Production

Description

Crizotinib, also known as PF-02341066, is an orally bioavailable agent belonging to the class of c-met/hepatocyte growth factor receptor (HGFR) tyrosine kinase inhibitors with potential antineoplastic activity. Crizotinib was approved for treatment of some non-small cell lung carcinoma (NSCLC) in the US, and undergoing clinical trials testing its safety and efficacy in anaplastic large cell lymphoma, neuroblastoma, and other advanced solid tumors in both adults and childre. Crizotinib inhibits the membrane receptor MET and activation of the MET signaling pathway, which may block tumor cell growth, migration and invasion, and tumor angiogenesis in susceptible tumor cell populations. Crizotinib was approved in 2011.

Uses

Crizotinib (PF-02341066) acetate is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC50s of 20 and 8 nM, respectively. Crizotinib acetate inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC50s of 24 and 11 nM in cell-based assays, respectively. Crizotinib acetate is also a ROS1 inhibitor. Crizotinib acetate has effective tumor growth inhibition[1][2][3].

References

[1] Zou HY, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 2007, 67(9), 4408-4417. DOI:10.1158/0008-5472.CAN-06-4443
[2] Christensen JG, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther. 2007, 6(12 Pt 1), 3314-3322. DOI:10.1158/1535-7163.MCT-07-0365
[3] Cui JJ, et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem. 2011 Sep 22;54(18):6342-63. DOI:10.1021/jm2007613

Crizotinib acetate Preparation Products And Raw materials

Raw materials

Preparation Products

Crizotinib acetate Suppliers

Global Suppliers ( 4)
Supplier Tel Email Country ProdList Advantage
Amadis Chemical Company Limited 571-89925085 sales@amadischem.com China 131885 58
TargetMol Chemicals Inc. +1-781-999-5354; +1-00000000000 marketing@targetmol.com United States 32431 58
TargetMol Chemicals Inc. 15002134094 marketing@targetmol.cn China 29874 58
TargetMol Chemicals Inc. +1-781-999-5354; support@targetmol.com United States 38999 58
Supplier Advantage
Amadis Chemical Company Limited 58
TargetMol Chemicals Inc. 58
TargetMol Chemicals Inc. 58
TargetMol Chemicals Inc. 58

View Latest Price from Crizotinib acetate manufacturers

Image Update time Product Price Min. Order Purity Supply Ability Manufacturer
Crizotinib acetate pictures 2026-07-27 Crizotinib acetate
877399-53-6
 $1670.00-2800.00 10g TargetMol Chemicals Inc.

877399-53-6 (Crizotinib acetate) Related Search:

2-Pyridinamine, 3-[(1S)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]- PF 02341066 hydrochloride 2-Keto Crizotinib 3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine (R)-5-(1-(7-azaspiro[3.5]nonan-2-yl)-1H-pyrazol-4-yl)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine
2-Pyridinamine, 3-[(1R)-1-(2-chloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-

1of2

Crizotinib acetate 877399-53-6